Whitehead Warren 4
4 · Aptose Biosciences Inc. · Filed Dec 28, 2020
Insider Transaction Report
Form 4
Whitehead Warren
Director
Transactions
- Exercise/Conversion
Common Shares
2020-12-22$2.01/sh+20,000$40,200→ 60,000 total - Sale
Common Shares
2020-12-22$4.11/sh−10,000$41,100→ 40,000 total - Exercise/Conversion
Director Stock Option (Right to Buy)
2020-12-22−20,000→ 20,000 totalExercise: $2.01From: 2019-01-02Exp: 2029-01-02→ Common Shares (40,000 underlying) - Sale
Common Shares
2020-12-22$4.01/sh−10,000$40,100→ 50,000 total
Footnotes (4)
- [F1]Converted from Canadian exercise price of C$2.60 using an exchange rate of C$1.2908 = US$1.00.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from C$5.16 to C$5.1924, inclusive. The reporting person undertakes to provide to Aptose Biosciences, Inc., any security holder of Aptose Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The weighted average sales price reported above was converted from the Canadian weighted average sales price of C$5.1745 using an exchange rate of C$1.2908 = US$1.00.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from C$5.2979 to C$5.3111, inclusive. The reporting person undertakes to provide to Aptose Biosciences, Inc., any security holder of Aptose Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The weighted average sales price reported above was converted from the Canadian weighted average sales price of C$5.3003 using an exchange rate of C$1.2908 = US$1.00.
- [F4]The options were granted on 1/2/2019 and fully vested on 1/2/2020.